Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-118 for the Treatment of CLN1 Disease
August 17 2021 - 7:00AM
Business Wire
Virtual event on Monday, August 30, 2021, at
10:00 a.m. ET will provide an overview of CLN1 disease, discuss
natural history, the TSHA-118 program and clinical development
strategy
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric,
pivotal-stage gene therapy company focused on developing and
commercializing AAV-based gene therapies for the treatment of
monogenic diseases of the central nervous system (CNS) in both rare
and large patient populations, today announced it will host a
virtual key opinion leader (KOL) webinar on TSHA-118 for the
treatment of CLN1 disease on Monday, August 30, 2021, from 10:00
a.m. to 12:30 p.m. ET.
The event will feature a presentation from key opinion leader
Angela Schulz, M.D., Ph.D., University Medical Center
Hamburg-Eppendorf, who will provide an overview of CLN1 disease, a
severe, neurodegenerative lysosomal storage disease with no
approved treatment, and discuss the natural history of the
disease.
Topics of discussion will also include the patient and caregiver
perspective on the burden of disease, preclinical pharmacology and
toxicology data for TSHA-118, and the clinical development strategy
for the TSHA-118 program. A question and answer session will follow
each formal presentation.
The event will feature presentations from:
- Sharon King, President of Taylor’s Tale, who will discuss the
burden of disease and provide a patient and caregiver
perspective
- Steven Gray, Ph.D., Associate Professor in the Department of
Pediatrics at UT Southwestern and Chief Scientific Advisor at
Taysha, who will review the preclinical and pharmacology data for
TSHA-118 for the treatment of CLN1 disease
- Suyash Prasad, MBBS, M.Sc., MRCP, MRCPCH, FFPM, CMO and Head of
R&D of Taysha, who will discuss the clinical development
strategy for TSHA-118
Registration for this event is available through LifeSci Events.
A live video webcast will be available in the “Events & Media”
section of the Taysha corporate website. An archived version of the
event will be available on the website for 60 days.
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to
eradicate monogenic CNS disease. With a singular focus on
developing curative medicines, we aim to rapidly translate our
treatments from bench to bedside. We have combined our team’s
proven experience in gene therapy drug development and
commercialization with the world-class UT Southwestern Gene Therapy
Program to build an extensive, AAV gene therapy pipeline focused on
both rare and large-market indications. Together, we leverage our
fully integrated platform—an engine for potential new cures—with a
goal of dramatically improving patients’ lives. More information is
available at www.tayshagtx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210817005281/en/
Company Contact: Kimberly Lee, D.O. SVP, Corporate
Communications and Investor Relations Taysha Gene Therapies
klee@tayshagtx.com
Media Contact: Carolyn Hawley Canale Communications
carolyn.hawley@canalecomm.com
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Apr 2023 to Apr 2024